$VTAK
Catheter Precision, Inc. Stock $vtak

$vtak Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000165495423015641 Filed on December 15, 2023

Income Statement

Concept	2023 Q4	2023 Q2	2023 Q1
Revenue	$128.0K	$96.00K	$85.00K
YoY Change		1820.0%	844.44%
Cost Of Revenue	$7.000K	$7.000K	$10.00K
YoY Change		-89.39%	-89.47%
Gross Profit	$121.0K	$89.00K	$75.00K
YoY Change		-245.9%	-187.21%
Gross Profit Margin	94.53%	92.71%	88.24%
Selling, General & Admin	$2.229M	$1.415M	$8.833M
YoY Change	-71.99%	-42.85%	283.71%
% of Gross Profit	1842.15%	1589.89%	11777.33%
Research & Development	-$11.00K	$134.0K	$240.0K
YoY Change	-107.14%	-94.41%	-92.3%
% of Gross Profit	-9.09%	150.56%	320.0%
Depreciation & Amortization	$517.0K	$9.000K	$1.444M
YoY Change	1968.0%	-91.0%	1344.0%
% of Gross Profit	427.27%	10.11%	1925.33%
Operating Expenses	$2.718M	$6.397M	$10.47M
YoY Change	-66.49%	-23.84%	93.34%
Operating Profit	-$2.597M	-$6.308M	-$10.40M
YoY Change	-67.99%	-25.44%	88.95%
Interest Expense	$72.00K	$119.0K	$69.00K
YoY Change		643.75%
% of Operating Profit
Other Income/Expense, Net	$1.856M	$4.732M	$15.00K
YoY Change	3045.76%	39333.33%	87.5%
Pretax Income	-$669.0K	-$1.576M	-$66.40M
YoY Change	-91.8%	-81.34%	1108.37%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$669.0K	-$1.576M	-$67.20M
YoY Change	-91.8%	-81.34%	1122.93%
Net Earnings / Revenue	-522.66%	-1641.67%	-79058.82%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.10	-$0.29	-$24.65
COMMON SHARES
Basic Shares Outstanding	7.027M shares		4.984M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q4	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.565M	$7.410M	$12.22M
YoY Change	-77.52%	-33.41%	-30.78%
Cash & Equivalents	$3.565M	$7.410M	$12.22M
Short-Term Investments
Other Short-Term Assets	$415.0K	$320.0K	$388.0K
YoY Change	-57.52%	-72.03%	-69.62%
Inventory	$44.00K	$59.00K	$70.00K
Prepaid Expenses
Receivables	$137.0K	$119.0K	$80.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.161M	$7.908M	$12.76M
YoY Change	-75.29%	-35.87%	-36.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$70.00K	$67.00K	$185.0K
YoY Change		76.32%	-88.84%
Goodwill	$0.00	$0.00	$0.00
YoY Change
Intangibles		$1.300M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$8.000K	$8.000K	$5.000K
YoY Change		-77.78%	-86.11%
Total Long-Term Assets	$26.58M	$27.63M	$35.75M
YoY Change		1253.94%	857.76%
TOTAL ASSETS
Total Short-Term Assets	$4.161M	$7.908M	$12.76M
Total Long-Term Assets	$26.58M	$27.63M	$35.75M
Total Assets	$30.74M	$35.54M	$48.51M
YoY Change	82.56%	147.28%	104.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$464.0K	$93.00K	$580.0K
YoY Change	404.35%	-80.9%	-50.47%
Accrued Expenses	$1.733M	$1.863M	$3.873M
YoY Change	-76.84%	-5.43%	70.39%
Deferred Revenue
YoY Change
Short-Term Debt	$184.0K	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.472M	$2.042M	$4.453M
YoY Change	-67.37%	-25.85%	19.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$7.071M	$9.709M	$8.193M
YoY Change		431.13%	330.3%
Total Long-Term Liabilities	$7.071M	$9.709M	$8.193M
YoY Change		431.13%	330.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.472M	$2.042M	$4.453M
Total Long-Term Liabilities	$7.071M	$9.709M	$8.193M
Total Liabilities	$9.543M	$11.75M	$12.65M
YoY Change	25.96%	156.46%	124.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$275.7M	-$273.1M
YoY Change	34.43%	42.1%
Common Stock	$296.9M	$296.9M
YoY Change	38.48%	46.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.19M	$23.79M	$35.86M
YoY Change
Total Liabilities & Shareholders Equity	$30.74M	$35.54M	$48.51M
YoY Change	82.56%	147.28%	104.27%

Cashflow Statement

Concept	2023 Q4	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	-$669.0K	-$1.576M	-$67.20M
YoY Change	-91.8%	-81.34%	1122.93%
Depreciation, Depletion And Amortization	$517.0K	$9.000K	$1.444M
YoY Change	1968.0%	-91.0%	1344.0%
Cash From Operating Activities	-$1.889M	-$4.847M	-$12.05M
YoY Change	-37.55%	-19.32%	40.15%
INVESTING ACTIVITIES
Capital Expenditures	$18.00K	$20.00K	$37.00K
YoY Change	5.88%
Acquisitions			-$15.00K
YoY Change
Other Investing Activities	$0.00	-$5.000K	$15.00K
YoY Change	-100.0%
Cash From Investing Activities	-$18.00K	-$20.00K	-$22.00K
YoY Change	-185.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-107.0K	59.00K	8.434M
YoY Change	-102.06%	-111.43%	-24.53%
NET CHANGE
Cash From Operating Activities	-1.889M	-4.847M	-12.05M
Cash From Investing Activities	-18.00K	-20.00K	-22.00K
Cash From Financing Activities	-107.0K	59.00K	8.434M
Net Change In Cash	-2.014M	-4.808M	-3.641M
YoY Change	-191.46%	-26.3%	-239.66%
FREE CASH FLOW
Cash From Operating Activities	-$1.889M	-$4.847M	-$12.05M
Capital Expenditures	$18.00K	$20.00K	$37.00K
Free Cash Flow	-$1.907M	-$4.867M	-$12.09M
YoY Change	-37.31%	-18.99%	40.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001716621
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2161950	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5367674	shares
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	vtak	Estimated Fair Value Royalty Payable EstimatedFairValueRoyaltyPayable	14000000.0	usd
CY2023Q2	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.06	pure
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.06	pure
CY2023Q1	vtak	Series F Warrants Exercisable SeriesFWarrantsExercisable	4999093	shares
CY2023Q1	vtak	Series G Warrants Exercisable SeriesGWarrantsExercisable	4999093	shares
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	0	usd
CY2023Q2	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	0	usd
	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	3.20
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38677
	dei	Entity Registrant Name EntityRegistrantName	Catheter Precision, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	38-3661826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1670 Highway 160 West
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Mill
	dei	Entity Address State Or Province EntityAddressStateOrProvince	SC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	29708
	dei	City Area Code CityAreaCode	973
	dei	Local Phone Number LocalPhoneNumber	691-2000
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	VTAK
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7026678	shares
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	86000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2042000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7576000	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	9565000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11751000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7576000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5367674	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2161950	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	0	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	296904000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273113000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23791000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35542000	usd
CY2023Q2	us-gaap	Revenues Revenues	96000	usd
CY2022Q2	us-gaap	Revenues Revenues	5000	usd
	us-gaap	Revenues Revenues	181000	usd
	us-gaap	Revenues Revenues	14000	usd
CY2023Q2	vtak	Cost Of Revenue Product Sales CostOfRevenueProductSales	7000	usd
CY2022Q2	vtak	Cost Of Revenue Product Sales CostOfRevenueProductSales	11000	usd
	vtak	Cost Of Revenue Product Sales CostOfRevenueProductSales	17000	usd
	vtak	Cost Of Revenue Product Sales CostOfRevenueProductSales	42000	usd
CY2023Q2	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	0	usd
CY2022Q2	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	55000	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	0	usd
	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	119000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	7000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	66000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	17000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	161000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	89000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	-61000	usd
	us-gaap	Gross Profit GrossProfit	164000	usd
	us-gaap	Gross Profit GrossProfit	-147000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1415000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2476000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11648000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4778000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2396000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	374000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5511000	usd
CY2023Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2022Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	3527000	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	3527000	usd
CY2023Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	4848000	usd
CY2022Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	60934000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	6397000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	8399000	usd
	us-gaap	Operating Expenses OperatingExpenses	72956000	usd
	us-gaap	Operating Expenses OperatingExpenses	13816000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6308000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8460000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72792000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13963000	usd
CY2023Q2	vtak	Change In Fair Value Of Royalty ChangeInFairValueOfRoyalty	4617	usd
CY2022Q2	vtak	Change In Fair Value Of Royalty ChangeInFairValueOfRoyalty	0	usd
	vtak	Change In Fair Value Of Royalty ChangeInFairValueOfRoyalty	4617	usd
	vtak	Change In Fair Value Of Royalty ChangeInFairValueOfRoyalty	0	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	119000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	0	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	188000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	0	usd
CY2023Q2	us-gaap	Other Income OtherIncome	4000	usd
CY2022Q2	us-gaap	Other Income OtherIncome	12000	usd
	us-gaap	Other Income OtherIncome	11000	usd
	us-gaap	Other Income OtherIncome	20000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4732000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4816000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1576000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8448000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-67976000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13943000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8448000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67976000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13943000	usd
CY2023Q2	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	0	usd
CY2022Q2	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	0	usd
	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	800000	usd
	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	0	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1576000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8448000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-68776000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13943000	usd
CY2023Q2	vtak	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.29
CY2022Q2	vtak	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-13.07
	vtak	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-16.97
	vtak	Earnings Per Shares Basic And Diluted EarningsPerSharesBasicAndDiluted	-0.03
CY2023Q2	vtak	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	5364383000	shares
CY2022Q2	vtak	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	646361000	shares
	vtak	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	4052700000	shares
	vtak	Weighted Average Number Of Shares Outstanding Basic And Diluted WeightedAverageNumberOfSharesOutstandingBasicAndDiluted	525924000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9260000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	179000	usd
CY2023Q1	vtak	Restricted Stock Awards Cancelled Amount RestrictedStockAwardsCancelledAmount	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1394000	usd
CY2023Q1	vtak	Issuance Of Series X Preferred Stock In Merger Amount IssuanceOfSeriesXPreferredStockInMergerAmount	82925000	usd
CY2023Q1	vtak	Conversion Of Series X Preferred Stock Amount ConversionOfSeriesXPreferredStockAmount	0	usd
CY2023Q1	vtak	Issuance Of Instruments In Connection With Private Placement Net Amount IssuanceOfInstrumentsInConnectionWithPrivatePlacementNetAmount	7360000	usd
CY2023Q1	vtak	Warrant Repricing Net Amount WarrantRepricingNetAmount	1145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-66400000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	35863000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	59000	usd
CY2023Q2	vtak	Adjustment Of Fair Value Of Series X Preferred Stock In Merger AdjustmentOfFairValueOfSeriesXPreferredStockInMerger	-10381000	usd
CY2023Q2	vtak	Adjustment Of Fair Value Stock Based Compensation Related To Merger AdjustmentOfFairValueStockBasedCompensationRelatedToMerger	-174000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1576000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	23791000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	13673000	usd
CY2022Q1	vtak	Common Stock And Warrants Issued Net Amount CommonStockAndWarrantsIssuedNetAmount	9740000	usd
CY2022Q1	vtak	Warrants Exercisedamount WarrantsExercisedamount	25000	usd
CY2022Q1	vtak	Vesting Of Restricted Stock Units And Awardsamount VestingOfRestrictedStockUnitsAndAwardsamount	0	usd
CY2022Q1	vtak	Restricted Stock Awards Cancelled Amount RestrictedStockAwardsCancelledAmount	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	165000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5495000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18108000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	usd
CY2022Q2	vtak	Restricted Stock Awards Cancelled Amount RestrictedStockAwardsCancelledAmount	0	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	126000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-8448000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9791000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-67976000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13943000	usd
	vtak	Restructuring Costs And Assets Impairment Charges RestructuringCostsAndAssetsImpairmentCharges	0	usd
	vtak	Restructuring Costs And Assets Impairment Charges RestructuringCostsAndAssetsImpairmentCharges	2943000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	60934000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1038000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	322000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1220000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	291000	usd
	vtak	Accretion Of Royalties Payable AccretionOfRoyaltiesPayable	-4617000	usd
	vtak	Accretion Of Royalties Payable AccretionOfRoyaltiesPayable	0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	44000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-48000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-57000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	680000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-502000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-921000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-501000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-7010000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3039000	usd
	vtak	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	-198000	usd
	vtak	Increase Decrease In Interest Payable IncreaseDecreaseInInterestPayable	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-139000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14577000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-15000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
	vtak	Proceeds From Issuance Of Common Stock And Warrants Net Fees Withheld ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld	238000	usd
	vtak	Proceeds From Issuance Of Common Stock And Warrants Net Fees Withheld ProceedsFromIssuanceOfCommonStockAndWarrantsNetFeesWithheld	12670000	usd
	vtak	Payments Of Offering Costs Related To The Issuance Of Common Stock And Warrants PaymentsOfOfferingCostsRelatedToTheIssuanceOfCommonStockAndWarrants	0	usd
	vtak	Payments Of Offering Costs Related To The Issuance Of Common Stock And Warrants PaymentsOfOfferingCostsRelatedToTheIssuanceOfCommonStockAndWarrants	-2040000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1326000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	25000	usd
	vtak	Proceeds From Issuance Of Common Stock In Connection With The Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockInConnectionWithTheEmployeeStockPurchasePlan	0	usd
	vtak	Proceeds From Issuance Of Common Stock In Connection With The Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockInConnectionWithTheEmployeeStockPurchasePlan	5000	usd
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	181000	usd
	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	usd
	vtak	Payments Of Convertible Promissory Notes And Accrued Interest PaymentsOfConvertiblePromissoryNotesAndAccruedInterest	-250000	usd
	vtak	Payments Of Convertible Promissory Notes And Accrued Interest PaymentsOfConvertiblePromissoryNotesAndAccruedInterest	0	usd
	vtak	Proceeds From The Private Placement Of Securities ProceedsFromThePrivatePlacementOfSecurities	8000000	usd
	vtak	Proceeds From The Private Placement Of Securities ProceedsFromThePrivatePlacementOfSecurities	0	usd
	vtak	Payments Of Offering Costs Related To The Private Placement Of Securities PaymentsOfOfferingCostsRelatedToThePrivatePlacementOfSecurities	-640000	usd
	vtak	Payments Of Offering Costs Related To The Private Placement Of Securities PaymentsOfOfferingCostsRelatedToThePrivatePlacementOfSecurities	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8493000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10660000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8449000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3917000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15859000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15045000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7410000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11128000	usd
	vtak	Unpaid Offering Costs UnpaidOfferingCosts	0	usd
	vtak	Unpaid Offering Costs UnpaidOfferingCosts	890000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	72544000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	198000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 1. Organization and Nature of Operations </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>The Company</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Catheter <span style="font-family:'times new roman'">Precision Inc. (formerly known as Ra Medical Systems, Inc.) (“Catheter” or the “Company” or “Legacy </span>Ra Medical” when speaking about historical operations pre-Merger (see below) is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System (“DABRA”), is used as a tool in the treatment of peripheral artery disease. The Company paused all engineering and manufacturing activities during the third quarter of 2022, including the development of a version of the DABRA catheter that is compatible with a standard interventional guidewire. The Company also paused research to prove the feasibility of using a DABRA-derived catheter technology to fracture calcium in arteries in a procedure known as lithotripsy. On July 5, 2022, the Company announced the receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for the DABRA 2.0 catheter as part of the DABRA Excimer Laser System. The Company suspended sales of DABRA during the year ended December 31, 2022 and currently has no plans to commercialize DABRA 2.0. The Company was formed on September 4, 2002 in the state of California and reincorporated in Delaware on July 14, 2018.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 9, 2023, the Company completed its acquisition of the former Catheter Precision, Inc., previously a privately held Delaware corporation (“Old Catheter”), which is focused on the cardiac electrophysiology market and now is a wholly owned limited liability company <span style="font-family:'times new roman'">subsidiary of the Company (the “Merger”). Following the Merge</span>, the Company began focusing on the field of cardiac electrophysiology (see Note 3, Business Combination). Catheter’s primary product is the View into Ventricular Onset (“VIVO” or “VIVO System”). VIVO is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. FDA 510(K) clearance in the United States was received and the Company began a limited commercial release of VIVO in 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, the Company’s Surgical Vessel Closing Pressure Device (“LockeT”) is a sterile, Class I product that was registered with the FDA in February 2023, at which time we began initial shipments to distributors. LockeT is indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure, and it is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Clinical studies for LockeT are planned to begin during 2023. These studies are planned to show the product’s effectiveness and benefits, including faster wound closure, earlier ambulation, potentially leading to early hospital discharge, and cost analysis. This data is intended to provide crucial data for marketing and to expand indications for use with the FDA.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to 2018, Old Catheter sold the AMIGO remote catheter system (the “AMIGO” or “AMIGO System”) which provides for accurate positioning, manipulation and stable control of catheters for use by electrophysiologists in the diagnosis and treatment of abnormal heart rhythms known as cardiac arrhythmias. The Company owns the intellectual property related to the AMIGO System. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Going Concern</strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of June 30, 2023, the Company had cash and cash equivalents of approximately $7.4 million. For the six months ended June 30, 2023, the Company used approximately $16.9 million in cash from operating activities. The Company has incurred recurring net losses from operations and negative cash flows from operating activities since inception. As of June 30, 2023, the Company had an accumulated deficit of approximately $273.1 million.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management expects operating losses and negative cash flows to continue for the foreseeable future as the Company invests in its commercial capabilities. Additional costs associated with the Merger paid during the year ended December 31, 2022 and during the six months ended June 30, 2023 have substantially depleted the Company’s cash. Following the Merger with Old Catheter, management further reduced staff and other costs while assuming the operating costs of Old Catheter. Of the Company’s cash flows used in operating activities of $16.9 million, much of these cash outflows are related to the Merger and are non-recurring in nature. Specifically, the Company paid approximately $5.0 million in settlement costs that had been accrued as of December 31, 2022 (see Note 8, Accrued Expenses). Management will continue to monitor its operating costs and seek to reduce its current liabilities. Such actions may impair its ability to proceed with certain strategic activities, and it may be unsuccessful at negotiating existing liabilities to the Company’s benefit. In January 2023, the Company raised gross proceeds of $1.3 million from a Warrant Repricing and, in March 2023, the Company completed a Private Placement and raised gross proceeds of $8.0 million (see Note 12, Equity Offerings). If expected revenues are not adequate to fund planned expenditures, or if the Company is unsuccessful at raising cash through future capital transactions, it may be required to reduce its spending rate to align with expected revenue levels and cash reserves, although there can be no guarantee that it will be successful in doing so. Accordingly, the Company may be required to raise additional cash through debt or equity transactions. It may not be able to secure financing in a timely manner or on favorable terms, if at all.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a result of these factors, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year after the date the unaudited financial statements are issued. The Company’s unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	7400000	usd
	vtak	Cash Flows Used In Operating Activities CashFlowsUsedInOperatingActivities	16900000	usd
CY2023Q2	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	273100000	usd
CY2022	vtak	Cash Flows Used In Operating Activities CashFlowsUsedInOperatingActivities	16900000	usd
CY2022Q4	vtak	Accued Settlement Costs AccuedSettlementCosts	5000000.0	usd
CY2023Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	14200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px">The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Catheter business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted. </p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;font-family:times new roman;margin:0px">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent highly liquid investments with maturities of 90 days or less at the date of purchase. Credit risk related to cash and cash equivalents are based on the creditworthiness of the financial institutions at which these funds are held. The Company has cash balances at financial institutions which throughout the year may exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. To reduce its risk associated with the failure of such financial institution, the Company evaluates the rating of the financial institution in which it holds deposits. Any material loss that the Company may experience in the future could have an adverse effect on its ability to pay its operational expenses or make other payments and may require the Company to move its cash to other high quality financial institutions. Currently, the Company is reviewing its bank relationships in order to mitigate its risk to ensure that its exposure is limited or reduced to the Federal Deposit Insurance Corporation protection limits.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</p>
CY2023Q2	us-gaap	Time Deposits At Or Above Fdic Insurance Limit TimeDepositsAtOrAboveFDICInsuranceLimit	6700000	usd
CY2023Q2	vtak	Mutual Fund MutualFund	7319	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1	usd
CY2023Q2	us-gaap	Assets Net AssetsNet	7320	usd
CY2023Q2	us-gaap	Other Notes Payable OtherNotesPayable	9565	usd
CY2023Q2	us-gaap	Other Liabilities OtherLiabilities	9565	usd
CY2022Q4	vtak	Mutual Fund MutualFund	300	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1436	usd
CY2022Q4	us-gaap	Assets Net AssetsNet	1736	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	89000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	369000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	192000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	192000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	129000	usd
	vtak	Scheduleofactivityintheaccountsreceivabletable Textblock ScheduleofactivityintheaccountsreceivabletableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Trade accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">271</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">152</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Reserve for expected credit losses/Allowance for doubtful accounts</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Accounts receivable, net</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">119</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	271000	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	152000	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	152000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	152000	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	119000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	372000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1863000	usd
CY2023Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4800000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	60900000	usd
	vtak	Description Related To Royalty DescriptionRelatedToRoyalty	The Company will pay to the Noteholders a total royalty equal to approximately 12% of net sales of LockeT, commencing upon the first commercial sale, through December 31, 2035
	vtak	Additional Description Related To Royalty AdditionalDescriptionRelatedToRoyalty	Old Catheter had entered into an agreement with the inventor of LockeT in exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on net sales up to $1 million in royalties and then 2% on LockeT net sales if a patent is granted. After $1 million has been paid, and if, and only if, a U.S. patent is granted by the United States Patent and Trademark Office, then the Company will continue to pay a royalty at a rate of 2% of LockeT net sales, until total cumulative royalties of $10 million have been paid
CY2023Q2	vtak	Royalties Payable RoyaltiesPayable	14200000	usd
	vtak	Royalty Payable Estimated Fair Value RoyaltyPayableEstimatedFairValue	9600000	usd
CY2023Q1	vtak	Royalty Liability Discount Rate RoyaltyLiabilityDiscountRate	0.241	pure
	vtak	Royalty Liability Discount Rate RoyaltyLiabilityDiscountRate	0.300	pure
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7484000	usd
CY2023Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	359000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	605000	usd
CY2022Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	69000	usd
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	13800000	usd
	vtak	Scheduleofactivityintheproductwarrantyaccrualisincludedinaccruedexpensestable Textblock ScheduleofactivityintheproductwarrantyaccrualisincludedinaccruedexpensestableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six months </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Year ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>December 31, </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at beginning of period</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">192</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:11%;vertical-align:bottom;text-align:right;">195</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Claims satisfied</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;vertical-align:bottom;text-align:right;">(3</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at end of period</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">192</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;vertical-align:bottom;text-align:right;">192</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	192000	usd
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	195000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	0	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3000	usd
CY2023Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	192000	usd
CY2023Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	800000	usd
CY2023Q1	vtak	Total Purchase Price Of Fair Value TotalPurchasePriceOfFairValue	72544	usd
CY2022	us-gaap	Development Costs DevelopmentCosts	35100000	usd
	us-gaap	Development Costs DevelopmentCosts	27000000.0	usd
CY2022Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1700000	usd
CY2023Q2	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	1300000	usd
CY2022Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	220000	usd
CY2023Q2	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	62000	usd
CY2022Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	56100000	usd
CY2023Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	60900000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7600000	usd
	vtak	Summaryofpreliminarypurchasepriceallocationstable Textblock SummaryofpreliminarypurchasepriceallocationstableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Description</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Fair Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Assets acquired:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Inventories</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">52</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expenses and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> Lease right-of-use assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">119</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Other assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Developed technology</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27,014</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Customer relationships</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">62</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Trademarks</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,285</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Goodwill</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">60,934</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total assets acquired</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">89,609</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Liabilities assumed:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">922</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accrued expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,389</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">198</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible promissory note</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease liability</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">124</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Royalties payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">14,182</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total liabilities assumed</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">17,065</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Total purchase price</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">72,544</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	28361000	usd
CY2023Q2	vtak	Goodwill Impairment Losses GoodwillImpairmentLosses	4800000	usd
CY2023Q2	vtak	Goodwill Balance Amount GoodwillBalanceAmount	0	usd
CY2023Q2	vtak	Asset Intangible Impairment Charges AssetIntangibleImpairmentCharges	60900000	usd
CY2023Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	0	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1700000	usd
	vtak	Scheduleofbasicanddilutednetlosspershareonaproformabasistable Textblock ScheduleofbasicanddilutednetlosspershareonaproformabasistableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Three Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Six Months Ended</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>June 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">96</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">146</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,576</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(9,906</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(68,146</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(16,872</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Net loss attributable to common stockholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,576</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(9,906</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(68,946</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(16,872</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per share – on a pro forma basis (unaudited)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(0.29</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(15.27</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(16.81</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">(31.97</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table>
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	44000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	15000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	59000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	192000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	82000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	0	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	0	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	67000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2023Q2	us-gaap	Depreciation Depreciation	9000	usd
	us-gaap	Depreciation Depreciation	15000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	63000	usd
	us-gaap	Depreciation Depreciation	179000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28361000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27339000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000.0	usd
	us-gaap	Goodwill Subsequent Recognition Of Deferred Tax Asset GoodwillSubsequentRecognitionOfDeferredTaxAsset	60900000	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	56100000	usd
CY2023Q2	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	4800000	usd
CY2023Q2	vtak	Cumulative Goodwill Impairment Charges CumulativeGoodwillImpairmentCharges	60900000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q1	vtak	Goodwill Recognized In Connection With The Merger GoodwillRecognizedInConnectionWithTheMerger	56086000	usd
CY2023Q1	vtak	Impairment Charge ImpairmentCharge	-56086000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	0	usd
CY2023Q2	vtak	Goodwill Recognized In Connection With The Merger GoodwillRecognizedInConnectionWithTheMerger	4848000	usd
CY2023Q2	vtak	Impairment Charge ImpairmentCharge	-4848000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	0	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	97000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5195000	usd
CY2023Q2	vtak	Accrued Offering Costs Current AccruedOfferingCostsCurrent	1356000	usd
CY2022Q4	vtak	Accrued Offering Costs Current AccruedOfferingCostsCurrent	1356000	usd
	vtak	Royalties Payable Texte Block RoyaltiesPayableTexteBlock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Note 9. Royalties Payable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>LockeT Royalty</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On January 9, 2023, the Company entered into an agreement with the Noteholders to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a total royalty equal to approximately 12% of net sales of its LockeT, commencing upon the first commercial sale, through December 31, 2035. The remaining accrued interest for the note not converted at closing of the Merger was paid on February 9, 2023. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">An additional royalty will be paid to the inventor of the LockeT in exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on LockeT net sales up to $1 million in royalties, payable annually in arrears, starting with the year ending December 31, 2022. After $1 million has been paid, and if, and only if, a U.S. patent is granted by the United States Patent and Trademark Office, then the Company will continue to pay a royalty at a rate of 2% of LockeT net sales, until total cumulative royalties of $10 million have been paid. The royalty payments will end on revenues earned through February 29, 2032, regardless if the total $10 million has been paid. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>AMIGO System Royalty</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter’s AMIGO System receiving a total of $1.6 million from the foundation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The agreement calls for the payment of the following sales-based royalties, by Old Catheter, to the foundation, upon successful commercialization of the AMIGO System:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Royalty Percentage</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Until Royalty Payment Reaches a Total of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,589,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,179,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">In perpetuity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company is not actively marketing and selling the AMIGO System. There was no royalty expense recorded for the three and six months ended June 30, 2023 and 2022 in relation to the AMIGO System. The AMIGO System royalty has been earned and payment has been deferred to a future date.</p><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px">See table below for a roll forward of the royalty payable for the six months ended June 30, 2023:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at beginning of period</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">AMIGO royalty payable assumed in connection with the Merger</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">159</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">LockeT royalty payable assumed in connection with the Merger</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14,022</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Change in fair value of royalty payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,617</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">) </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in"><strong>Balance at end of period</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">9,565</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
	vtak	Locket Royalty Description LocketRoyaltyDescription	An additional royalty will be paid to the inventor of the LockeT in exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on LockeT net sales up to $1 million in royalties, payable annually in arrears, starting with the year ending December 31, 2022. After $1 million has been paid, and if, and only if, a U.S. patent is granted by the United States Patent and Trademark Office, then the Company will continue to pay a royalty at a rate of 2% of LockeT net sales, until total cumulative royalties of $10 million have been paid
	us-gaap	Payments For Royalties PaymentsForRoyalties	10000000	usd
	vtak	Summaryofsalesbasedroyaltiestable Textblock SummaryofsalesbasedroyaltiestableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Royalty Percentage</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-TOP: medium none; BORDER-BOTTOM: 0.5pt solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Until Royalty Payment Reaches a Total of </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,589,500</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,179,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1%</p></td><td style="width:1%;white-space: nowrap;"></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">In perpetuity</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4	vtak	Royalty Payable RoyaltyPayable	0	usd
	vtak	Amigo Royalty Payable Recognized In Connection With The Merger AmigoRoyaltyPayableRecognizedInConnectionWithTheMerger	159000	usd
	vtak	Locket Royalty Payable Recognized In Connection With The Merger LocketRoyaltyPayableRecognizedInConnectionWithTheMerger	14022000	usd
	vtak	Accretion Of Royalties Payable AccretionOfRoyaltiesPayable	-4617000	usd
CY2023Q2	vtak	Royalty Payable RoyaltyPayable	9565000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	16713	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	28796	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	110057	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	220113	usd
	vtak	Operating Lease Weighted Average Remaining Lease Term OperatingLeaseWeightedAverageRemainingLeaseTerm	P2Y6M7D
CY2023Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0878	pure
	vtak	Rent Expense RentExpense	3200	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	47000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	96000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	81000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	14000	usd
CY2023Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	238000	usd
CY2023Q2	vtak	Finance Lease Liabilitydiscounted Amount FinanceLeaseLiabilitydiscountedAmount	-8000	usd
CY2023Q2	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	230000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	990	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11405
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	220000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	0	usd
CY2023Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	220000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	86000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	230000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0	usd
	us-gaap	Dividends Dividends	800000	usd
	vtak	Repriced Warrants RepricedWarrants	300000	usd
	vtak	Series E Warrants Value SeriesEWarrantsValue	1900000	usd
CY2023Q2	us-gaap	Dividends Dividends	0	usd
	us-gaap	Dividends Dividends	800000	usd
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11042151	shares
	vtak	Weighted Average Exercise Price WeightedAverageExercisePrice	5.31
CY2023Q1	vtak	Common Stock Capital Shares Weighted Average Exercise Price CommonStockCapitalSharesWeightedAverageExercisePrice	3.00
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	215330	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	61	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	450
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	26	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	333
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	9	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1129
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	26	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	333
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	174000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	123000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1220000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	291000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001	pure
	vtak	Description Of Research And Development Amounts Amortized DescriptionOfResearchAndDevelopmentAmountsAmortized	research and development in the U.S., the amounts will be amortized over 5 years, and expenses that are incurred for research and experimentation outside the U.S. will be amortized over 15 years
	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	all full-time employees were eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company made matching contributions based on 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employee’s eligible compensation
CY2022Q2	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	100000	usd
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	200000	usd
CY2023Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	25100000	usd
CY2023Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	7856	shares
CY2023Q2	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	13900000	usd
	us-gaap	Business Combination Control Obtained Description BusinessCombinationControlObtainedDescription	Mr. Jenkins and his affiliates received 1,325.838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkins’ adult children received 1,284.344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Catheter in accordance with the merger exchange ratio.
CY2023Q2	vtak	Accrued Expenses AccruedExpenses	1400000	usd

Files In Submission

Name	View Source	Status
0001654954-23-015641-index-headers.html	Edgar Link	pending
0001654954-23-015641-index.html	Edgar Link	pending
0001654954-23-015641.txt	Edgar Link	pending
0001654954-23-015641-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vtak-20230630.xsd	Edgar Link	pending
vtak_10q.htm	Edgar Link	pending
vtak_ex311.htm	Edgar Link	pending
vtak_ex312.htm	Edgar Link	pending
vtak_ex321.htm	Edgar Link	pending
vtak_ex322.htm	Edgar Link	pending
vtak-20230630_cal.xml	Edgar Link	unprocessable
vtak-20230630_lab.xml	Edgar Link	unprocessable
vtak-20230630_def.xml	Edgar Link	unprocessable
vtak-20230630_pre.xml	Edgar Link	unprocessable
vtak_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VTAK
Catheter Precision, Inc. Stock $vtak

2023 Q4 Form 10-Q Financial Statement

#000165495423015641 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTAK Catheter Precision, Inc. Stock $vtak

2023 Q4 Form 10-Q Financial Statement

#000165495423015641 Filed on December 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VTAK
Catheter Precision, Inc. Stock $vtak